| General Information | |
|---|---|
| ZINC ID | ZINC000045255250 |
| Molecular Weight (Da) | 331 |
| SMILES | CCC1(C(=O)Nc2cc(CN3CCOCC3)c(C)cn2)CCCC1 |
| Molecular Formula | C19N3O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 95.658 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 24 |
| LogP | 3.132 |
| Activity (Ki) in nM | 12.882 |
| Polar Surface Area (PSA) | 54.46 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | 0 |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 0.61060512 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.68 |
| Ilogp | 2.91 |
| Xlogp3 | 2.44 |
| Wlogp | 2.41 |
| Mlogp | 1.93 |
| Silicos-it log p | 3.61 |
| Consensus log p | 2.66 |
| Esol log s | -3.22 |
| Esol solubility (mg/ml) | 0.199 |
| Esol solubility (mol/l) | 0.000601 |
| Esol class | Soluble |
| Ali log s | -3.23 |
| Ali solubility (mg/ml) | 0.197 |
| Ali solubility (mol/l) | 0.000593 |
| Ali class | Soluble |
| Silicos-it logsw | -5.14 |
| Silicos-it solubility (mg/ml) | 0.00238 |
| Silicos-it solubility (mol/l) | 0.00000718 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.59 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 0 |
| Synthetic accessibility | 2.89 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.414 |
| Logd | 3.386 |
| Logp | 3.006 |
| F (20%) | 0.682 |
| F (30%) | 0.005 |
| Mdck | 1.15E-05 |
| Ppb | 0.5282 |
| Vdss | 1.288 |
| Fu | 0.4388 |
| Cyp1a2-inh | 0.099 |
| Cyp1a2-sub | 0.709 |
| Cyp2c19-inh | 0.737 |
| Cyp2c19-sub | 0.755 |
| Cl | 8.008 |
| T12 | 0.454 |
| H-ht | 0.317 |
| Dili | 0.038 |
| Roa | 0.931 |
| Fdamdd | 0.657 |
| Skinsen | 0.106 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.837 |
| Bcf | 0.202 |
| Igc50 | 2.006 |
| Lc50 | 2.999 |
| Lc50dm | 3.878 |
| Nr-ar | 0.11 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.76 |
| Nr-aromatase | 0.864 |
| Nr-er | 0.199 |
| Nr-er-lbd | 0.01 |
| Nr-ppar-gamma | 0.005 |
| Sr-are | 0.211 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.129 |
| Sr-mmp | 0.074 |
| Sr-p53 | 0.057 |
| Vol | 351.536 |
| Dense | 0.942 |
| Flex | 0.263 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 0.922 |
| Synth | 3.214 |
| Fsp3 | 0.684 |
| Mce-18 | 43.562 |
| Natural product-likeness | -0.879 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Accepted |